April 16, 2018
ReCell pivotal trial in the treatment of deep full-thickness (third-degree) burns with the RECELL® Autologous Cell Harvesting Device achieved its co-primary endpoints, demonstrating a statistically significant reduction in donor skin requirements versus standard of care while achieving comparable definitive wound closure.
The results were presented at the American Burn Association (ABA) 50th Annual Meeting in Chicago by James H. Holmes, IV, MD, FACS, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
“Treatment with the RECELL Device achieved comparable healing, long-term scar and patient satisfaction outcomes using significantly less donor skin with no safety concerns,” said Dr. Holmes. “I have had the opportunity to evaluate RECELL through several clinical trials and the FDA-approved Compassionate Use Program. I believe that the RECELL Device provides the opportunity to improve care for patients with severe burns.”
Avita Medical reports the RECELL Device is an investigational medical device in the U.S. that is designed to enable medical professionals to produce, at the point-of-care, a REGENERATIVE EPIDERMAL SUSPENSION™ (RES™) using a small sample of the patient’s own skin. The autologous suspension contains cells necessary to regenerate epidermis and provides a new way to achieve permanent closure in burns and other wounds while reducing the amount of skin harvested at the time of surgery. Reduction in donor-site skin requirements has important benefits from both clinical and health economic perspectives.
The presentation by Dr. Holmes, “Demonstration of the Safety and Effectiveness of Autologous Skin Cell Suspension Combined with Meshed Skin Grafts for the Reduction of Donor Area in the Treatment of Acute Burns,” described the outcomes from the controlled clinical trial conducted at seven U.S. burn centers. During the pivotal trial, the patient donor skin required to be harvested to treat burn sites with the RECELL Device was 32 percent less than the amount harvested to treat burn sites with the standard of care (p<0.001).
Despite the statistically significant reduction in donor skin required to treat with the RECELL Device, burn sites treated with the RECELL Device achieved definitive closure comparable to the burn sites treated with standard of care. At eight weeks post treatment, 92 percent of the burn sites treated with RECELL achieved complete healing versus 85 percent for the sites treated with the standard of care, demonstrating non-inferiority. Use of RECELL was safe and well tolerated with no treatment-related adverse events considered device related.
Avita Medical notes the pivotal trial evaluated 30 patients ranging in age from nine to 68 years old with thermal, mixed-thickness burns, including full-thickness burns, covering five percent to 46 percent of their total body surface area. Patients served as their own control, and two comparable burn sites were selected for comparative testing on each patient. One burn site was treated with the standard treatment, meshed autograft, while the other was treated with the combination of the RECELL Device and more widely meshed autografted (for example, if a 2:1 meshed autograft was used to treat the control burn site, then a 3:1 meshed autograft was used to treat the RECELL site). The co-primary endpoints of the pivotal trial were reduction in donor skin requirements and non-inferiority in complete wound closure.
The Biomedical Advanced Research and Development Authority (BARDA), under the Assistant Secretary for Preparedness and Response, within the US Department of Health and Human Services has provided funding under Contract No. HHSO100201500028C to support the development of RECELL by AVITA Medical, including the Compassionate Use program included in the presentation today.